Boehringer Ingelheim Zongertinib Shows Strong NSCLC Results
INGELHEIM, Germany, April 16, 2026 Boehringer Ingelheim has announced the publication of Phase 1b Beamion LUNG-1 trial results for...
Zongertinib
Advertisement
FDA Grants Priority Approval to Hernexeos for NSCLC
WASHINGTON, D.C., February 26, 2026 The U.S. Food and Drug Administration (FDA) has granted approval to Hernexeos (zongertinib) for...
FDA Grants Breakthrough Therapy Designation to HERNEXEOS® for First-Line Treatment of HER2-Mutant Advanced NSCLC
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for HERNEXEOS®...
Advertisement
